Website Design by 

Lamnia-Logo-White-PNG.png

ANNOVIS BIO
1055 Westlakes Drive
Suite 300

Berwyn, PA 19312

(c) 2019 Annovis Bio, All Rights Reserved 

The Causes of NEURODEGENERATION

and How We Work to Limit Its Progress

 

WHAT IS NEURODEGENERATION

The buildup of neurotoxic proteins impede healthy axonal transport

NORMAL BRAIN
with normal levels of AB, tau and αSYN.

BRAIN DAMAGE
with an increase in aggregating proteins

reduces neurotoxic proteins and improves brain chemistry

Our Solution to Reverse Neurodegeneration

ANVS401 is a small lipophilic molecule that is orally available and readily enters the brain as demonstrated by pharmacokinetic analyses showing brain concentrations approximately 6 to 8 times higher than plasma concentrations. ANVS401 has a unique mechanism of action in that it inhibited the translation and, therefore, the levels of several key neurotoxic proteins both in vitro and in vivo including APP, tau and αSYN.

Brain injuries and stresses lead to increases in neurotoxic proteins, impaired axonal transport and nerve cell death – neurodegenerative diseases

 

OUR MECHANISMS OF ACTION

A Three-Prong Attack on AD and PD

 We believe ANVS401 is the only drug in development that targets multiple neurotoxic proteins. Attacking one improve axonal transport in DS, AD and PD.  The multiple conditions we will target include;

 We Are Dedicated to Reversing Debilitating  Neurodegenerative Diseases

By targeting multiple neurotoxic proteins, ANVS401 resembles a combination therapy approach, with the added convenience of being a single drug with a single drug target. Therefore, we have worked to understand how ANVS401 is able to inhibit the translation of more than one neurotoxic protein.

 

DOCUMENT LIBRARY

Patents

2019 US Patent 10,383,851

2018 Use of MOA for Prevention and Treatment Application

2017 US 20180228771 Acute brain and nerve injuries Application

2012 US Patent 8,258,172 Dementia

2012 US 20120225922 Neurodegeneration Application

2010 US Patent 7,786,162 Methods for Treating Dementia

2009 US Patent 7,625,942 Down Syndrome

2006 US Patent 7,153,882 Pos Composition + Use

2002 US Patent 6,495,700 Process